Please login to the form below

Not currently logged in
Email:
Password:

Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company

Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  

She joined the company in 2009 as VP of business development and, since 2011, had served as senior vice president and chief business officer and sat on Zealand's executive management team.  

David Solomon, Zealand's president and CEO, said: “Arvind Hundal has made valuable contributions to building Zealand's large portfolio of partnership agreements over the past five years.  

“It is to a large extent also thanks to Arvind and the team's achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavours.”  

Before joining Zealand Dr Hundal, who has over 20 years of experience in the life sciences sector, served as a member of AstraZeneca's strategic planning business development organisation and as business development director at Danish biotech 7TM Pharma.

15th December 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....